SAN FRANCISCO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. ("Excision", the "Company"), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious ...
Announcing a new publication for Acta Materia Medica journal. Owing to environmental and lifestyle changes in modern society, physical and mental stress is on the rise among the population in ...
A drug currently prescribed to treat a rare enzyme deficiency can help cells clear the herpes simplex 1 and herpes simplex 2 viruses, according to a new study published in the journal Science Advances ...
In a recent study published in Communications Biology, researchers evaluated the therapeutic efficacy of Navoximod, combined with herpes simplex 1 (HSV-1) virotherapy, against hepatocellular carcinoma ...
A recent study In Press at the Journal of Cell Biology reports that herpes simplex virus 1 (HSV-1) exploits heterochromatin to successfully exit the nucleus. The heterochromatin markers macroH2A1 and ...
“To completely cure HSV-1, the idea is to prevent the virus from going into latency, because then, it’s protected by our own bodies,” said Esther González-Almela, a virologist at the Guangdong Academy ...
Herpes simplex virus is a common infection that typically appears in and around the mouth (oral herpes) or the genitals (genital herpes). Ulcers may cause pain but usually resolve within a few days or ...
- Treatment with EBT-104 led to complete elimination of viral shedding in 92% eyes of treated rabbits - Excision’s proprietary gene editing technology holds unique, curative potential to address the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback